KBI Biopharma
VC Fund
Durham, United States
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully-integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally.With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug developmentprograms. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San Diego (CA), and Leuven, Belgium.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries KBI Biopharma invests in
Stages KBI Biopharma invests in
Countries KBI Biopharma invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Investment Focus
Industry
- Biotechnology 3 (100%)
- Life Science 2 (67%)
- Medical 1 (33%)
- Biopharma 1 (33%)
- Therapeutics 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Series D 1 (33%)
Country
- United States 2 (67%)
- Ireland 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Abhinav Shukla
Sr. Vice President, Process Development and Manufacturing
|
Sr. Vice President, Process Development and Manufacturing | Total investments: 0 | Find email | |
Dirk T. Lange
CEO & President
|
CEO & President | Total investments: 0 | Find email | |
Doris Michor
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
Jesse Kingg
VP Manufacturing & Site Head Commercial Mfg. Facility
|
VP Manufacturing & Site Head Commercial Mfg. Facility | Total investments: 0 | Find email | |
Marykay Marchigiani
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process.Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. | $10.4M / Series D / Jan 07, 2019 | ||
| ReForm Biologics is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient toproduce. It was founded in 2014 and is based in Woburn, Massachusetts. | Series A / Apr 04, 2018 | ||
| GlycoSeLect specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs), enhanced tools for the analysis and selective purification of glycosylated biomolecules. RPLs have a broad spectrum of applications across the life sciences in:- Basic R&D – Glycobiology & Glycoproteomics.- Biomarker Discover &Biomedical Diagnostics.- The Biopharmaceutical Industry.- Vaccines- CosmeticsGlycoSeLect's Recombinant Prokaryotic Lectins (RPLs) present significant advantages over existing commercially available lectins products including:- Simplified, rapid & cost effective production through recombinant expression in Escherichia coli.- High purity & consistent performance.- Genetically enhanced glycan binding properties (specificity & affinity).- Scalable production facilitating utilization for large scale applications. | $529.2K / Seed / Oct 24, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does KBI Biopharma invest in?
KBI Biopharma invests primarily in Biotechnology, Life Science and Medical startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact KBI Biopharma?
Public channels for KBI Biopharma include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at KBI Biopharma?
The team at KBI Biopharma includes Abhinav Shukla (Sr. Vice President, Process Development and Manufacturing), Dirk T. Lange (CEO & President) and Doris Michor (Chief Operating Officer), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
